Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma June 26, 2024
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B June 4, 2024
TScan Receives FDA’s Regenerative Medicine Advanced Therapy Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies May 29, 2024
Longwood Healthcare Leaders Spring MIT to Convene Life Science Thought Leaders at MIT Koch Institute May 28, 2024
